Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx (MDXG) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Mimedx (MDXG) over the last 14 years, with Q3 2025 value amounting to $83000.0.

  • Mimedx's Gains from Investment Securities fell 2454.55% to $83000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 1290.56%. This contributed to the annual value of $2.6 million for FY2024, which is 147202.38% up from last year.
  • According to the latest figures from Q3 2025, Mimedx's Gains from Investment Securities is $83000.0, which was down 2454.55% from $526000.0 recorded in Q2 2025.
  • Over the past 5 years, Mimedx's Gains from Investment Securities peaked at $3.2 million during Q1 2021, and registered a low of -$1000.0 during Q4 2022.
  • In the last 5 years, Mimedx's Gains from Investment Securities had a median value of $160000.0 in 2021 and averaged $738562.5.
  • Per our database at Business Quant, Mimedx's Gains from Investment Securities crashed by 9966.41% in 2023 and then skyrocketed by 5370000.0% in 2024.
  • Quarter analysis of 5 years shows Mimedx's Gains from Investment Securities stood at $188000.0 in 2021, then crashed by 100.53% to -$1000.0 in 2022, then surged by 13300.0% to $132000.0 in 2023, then tumbled by 77.27% to $30000.0 in 2024, then skyrocketed by 176.67% to $83000.0 in 2025.
  • Its Gains from Investment Securities was $83000.0 in Q3 2025, compared to $526000.0 in Q2 2025 and $2.5 million in Q1 2025.